Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Operating Officer | March 17, 2020 | March 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date March 17, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,490 |
Reported balance
After 2020-03-17 transaction · row 1
1 source rowRow 1 · 2020-03-17 · Purchase · Acquired 2,840 · Balance 35,490 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2020 Filed Mar 18, 2020 15:21 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,840 | $3.54 | $10,053.60 |
DisclosureSEC source: 0001209191-20-019931 · doc4.xml · nonDerivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,490 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:24 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017400 · doc4.xml · derivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 14:57 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,500 | $4.62 | $11,558.50 |
DisclosureSEC source: 0001209191-19-055918 · doc4.xml · nonDerivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,650 Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 14:18 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 15,000 | $5.86 | $87,894.00 |
DisclosureSEC source: 0001209191-19-045442 · doc4.xml · nonDerivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,150 Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 13:22 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 100,000 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001209191-19-045053 · doc4.xml · derivative · entry 1 Discordia Robert Paul · CIK 0001784644 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-08-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on August 6, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 6, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.